Clinical trial NCT00469378: Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
Official title: An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Sclerosis
Keywords: firategrast
lymphocytes
leukocytes
SB-683699
cerebrospinal fluid
relapsing forms of multiple sclerosis
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-05-04
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast. Cerebrospinal fluid flows through and protects the brain and spinal cord. It is important to understand what happens to the number of white blood cells because they are important in preventing infections.


Eligibility criteria: Inclusion criteria:

Specific information regarding warnings, precautions, contraindications, adverse events (AEs), and other pertinent information on the investigational product that may impact subject eligibility is provided can be found in the SB-683699 Investigators Brochure \[GlaxoSmithKline Document Number HM2002/00094/05\].

Subjects eligible for enrollment in the study must meet all of the following criteria:

* Written informed consent.
* Male or female, age 18 to 65.
* A diagnosis of a relapsing form of MS \[As per McDonald, 2001; Polman, 2005\], with dissemination in time and space.
* Expanded Disability Status Scale (EDSS) score of between 0 and 6.5 inclusive.
* Occurrence of at least one clinical attack in the previous 24 months, but not within the 4 weeks prior to Screening or prior to the Baseline Visit.
* A minimum of two T2 lesions on brain MRI at Screening, as determined by the central MRI analysis reader.
* A female subject is eligible to enter the study if she is:

  1. Of non-childbearing potential, i.e. a woman who:

     * has documented evidence of tubal ligation, bilateral oophorectomy or hysterectomy; or
     * is post-menopausal, defined as at least one year without menses in the absence of hormone replacement therapy. In questionable cases, menopausal status will be confirmed by estradiol and Follicle Stimulating Hormone (FSH) levels consistent with menopause according to local laboratory ranges. Estrogen-containing hormone replacement therapies (HRT) are not allowed during the study.

     OR
  2. Of childbearing potential, has a negative urine pregnancy test at Screening and Baseline, and agrees to consistent and correct use the method of contraception listed below. Subjects will use effective contraceptive methods for at least one month prior to Screening and should continue to use the same contraceptive method throughout the study until 3 days after the last dose of firategrast.

     * Progesterone-only oral contraceptives or implants (inserted at least one month prior to Screening, but not beyond the third successive year following insertion). Estrogen-containing contraceptives are not allowed during the study.
     * Intrauterine Device (IUD) (inserted by a qualified clinician, with published data showing that the highest expected failure rate is less than 1% per year).
     * Spermicide in conjunction with either a diaphragm, cervical cap or condom.
     * Male partner sterilization (vasectomy) prior to female subject's entry into the study and is the sole partner for that female subject.

Exclusion criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

* Subjects receiving corticosteroids within 4 weeks of Screening for treatment of MS. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator after discussion with the GSK medical monitor.
* Use of a b-interferon product, glatiramer acetate or azathioprine within 3 months of Screening, or use of Mitoxantrone within 12 months of Screening. Subjects who have received other therapies affecting the immune system (such as intravenous immunoglobulin (IVIg), cyclophosphamide, plasmapheresis, or any other immunosuppressive or immunomodulatory treatment) in the past may be included on a case by case basis after discussion with the GSK medical monitor. None of these treatments will be allowed during this study.
* Previous exposure to alemtuzumab, natalizumab or firategrast administration, bone marrow transplantation or whole body irradiation.
* Subjects with a cardiac pacemaker or any other type of metal implant or with any other contraindication for MRI (including known allergy to gadolinium).
* Use of 4-aminopyridine, rosiglitazone, pioglitazone or any drug that is an inhibitor of or a substrate (with a low therapeutic index) for Organic Anion Transporter Protein (OATP).
* Subjects with clinically significant renal laboratory values: subjects with a calculated creatinine clearance \<60ml/min (by Cockcroft and Gault) at Screening \[Cockcroft, 1976\].
* Subjects with local urinalysis findings of 1) proteinuria, defined as ³1+ protein on urine dipstick or 2) renal tubular cell casts or 3) ³5 red blood cells / high power field will be excluded from the study if the result is still present on a repeat urinalysis during the Screening Phase.
* Presence of clinically significant hepatic laboratory values: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT) \> 2 times the upper limit of the reference range; total bilirubin \> 1.5 the upper limit of the normal range.
* CD4 count \< 500, CD4:CD8 \< 1.0, JCV viremia in plasma or white cells, idiopathic CD4/CD8 lymphopenia or secondary lymphopenia at Screening.
* Any findings at Screening on the MRI of the brain other than MS, except for benign findings that (in the opinion of the central MRI reading site and local site investigator) require no further evaluation or treatment and do not impact patient's neurological health (e.g. small arachnoid cysts, venous angiomas).
* Uncontrolled or any active bacterial, viral, or fungal infection. Any previous serious infections should be discussed with the GSK medical monitor (e.g. opportunistic or atypical infections).
* History of tuberculosis (TB) or positive chest X-ray for TB at Screening (prior chest X-ray is acceptable if performed within previous 6 months).
* Known congenital or acquired immunodeficiency.
* Current or history of cancer, excluding localized non-melanoma skin cancer.
* Any abnormality on 12-lead Electrocardiogram (ECG) at Screening which is clinically significant in the opinion of the investigator.
* Positive hepatitis B surface antigen, hepatitis C antibody or HIV tests at Screening.
* Women who are lactating, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the course of the study.
* Recent history or suspicion of current drug abuse (including analgesic abuse) or alcohol abuse within the last 6 months prior to Screening. Alcohol abuse is defined as an average weekly intake of greater than 21 units for men and 14 units for women or an average daily intake of greater than three units for men and two units for women. One unit is equivalent to approximately 250mL of beer or one measure of spirits or one glass of wine.
* Use of an investigational drug for a condition other than MS within 30 days or 5 half-lives (whichever is longer) preceding Screening. Prior use of an investigational drug for MS should be discussed with the GSK medical monitor.
* Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol.
* Contraindications, in the opinion of the investigator, to lumbar puncture, e.g. congenital or acquired spine or CNS conditions that may render LPs unsafe, platelet count of less than 50 GI/L and/or an International Normalized Ratio (INR) of greater than or equal to 1.5 (by history), known history of clotting/bleeding disorder, needle phobia.

Primary outcomes:
measure: Assessment of total leukocytes in cerebrospinal fluid (CSF)
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in number of total leukocytes in CSF
timeFrame: Baseline (Week 0) and Week 24, 28 and 36
measure: Assessment of total leukocytes in blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in number of total leukocytes in blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Assessment of total lymphocytes in CSF
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in number of total lymphocytes in CSF
timeFrame: Baseline (Week 0) and Week 24, 28, 36
measure: Assessment of total lymphocytes in blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in number of total lymphocytes in blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Assessment of lymphocyte subsets in CSF (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in number of lymphocyte subsets in CSF (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)
timeFrame: Baseline (Week 0) and Week 24, 28, 36
measure: Assessment of lymphocyte subsets in blood (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in number of lymphocyte subsets in blood (CD3+CD4+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD4-CD8-)
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Assessment of lymphocyte subset CD4 count in CSF
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in lymphocyte subset CD4 count in CSF
timeFrame: Baseline (Week 0) and Week 24, 28, 36
measure: Assessment of lymphocyte subset CD4 count in blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in lymphocyte subset CD4 count in blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Assessment of lymphocyte subset CD8 count in CSF
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in lymphocyte subset CD8 count in CSF
timeFrame: Baseline (Week 0) and Week 24, 28, 36
measure: Assessment of lymphocyte subset CD8 count in blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in lymphocyte subset CD8 count in blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Assessment of CD4:CD8 ratio in CSF
timeFrame: Baseline (Week 0), Week 24, 28 and 36
measure: Change from Baseline in CD4:CD8 ratio in CSF
timeFrame: Baseline (Week 0) and Week 24, 28, 36
measure: Assessment of CD4:CD8 ratio in blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in CD4:CD8 ratio in blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
Secondary outcomes:
measure: Assessment of CD34+ cells in the blood
timeFrame: Baseline (Week 0), Week 4, 24, 28 and 36
measure: Change from Baseline in number of CD34+ cells in the blood
timeFrame: Baseline (Week 0) and Week 4, 24, 28, 36
measure: Number of participants with adverse events (AEs) and Serious adverse events (SAEs)
timeFrame: Up to Week 24
measure: Cumulative number of new gadolinium-enhancing lesions at Week 24
timeFrame: Week 24
measure: Cumulative volume of new gadolinium-enhancing lesions at Week 24
timeFrame: Week 24
measure: Cumulative number of persistent gadolinium-enhancing lesions at Week 24
timeFrame: Week 24
measure: Cumulative total number of enhancing Lesions at Week 24
timeFrame: Week 24
measure: Plasma and CSF levels of firategrast
timeFrame: Week 24, 28 and 36
measure: The relationship between plasma concentration of firategrast and lymphocyte count in the CSF
timeFrame: Week 24, 28 and 36
measure: The relationship between plasma concentration of firategrast and lymphocyte count in the blood
timeFrame: Week 24, 28 and 36
measure: The relationship between the presence of the A allele of rs887829 and bilirubin levels
timeFrame: Baseline (Week 0)
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: GSK Investigational Site
city: Bruxelles
country: Belgium
facility: GSK Investigational Site
city: Olomouc
country: Czech Republic
facility: GSK Investigational Site
city: Praha 2
country: Czech Republic
facility: GSK Investigational Site
city: Glostrup
country: Denmark
facility: GSK Investigational Site
city: Koebenhavn Ø
country: Denmark
facility: GSK Investigational Site
city: Lørenskog
country: Norway
facility: GSK Investigational Site
city: Göteborg
country: Sweden
facility: GSK Investigational Site
city: Stockholm
country: Sweden
facility: GSK Investigational Site
city: Umeå
country: Sweden
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: